These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 28833844)

  • 1. How to design the cost-effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework.
    Johannesen KM; Claxton K; Sculpher MJ; Wailoo AJ
    Health Econ; 2018 Feb; 27(2):e41-e54. PubMed ID: 28833844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.
    Goetghebeur MM; Wagner M; Khoury H; Levitt RJ; Erickson LJ; Rindress D
    Med Decis Making; 2012; 32(2):376-88. PubMed ID: 21987539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of economic appraisal of health technology in the European Community: report of the network. The EC Network on the Methodology of Economic Appraisal of Health Technology.
    Davies L; Coyle D; Drummond M
    Soc Sci Med; 1994 Jun; 38(12):1601-7. PubMed ID: 8047917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.
    Hettle R; Corbett M; Hinde S; Hodgson R; Jones-Diette J; Woolacott N; Palmer S
    Health Technol Assess; 2017 Feb; 21(7):1-204. PubMed ID: 28244858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Morgan P; Woolacott N; Biswas M; Mebrahtu T; Harden M; Hodgson R
    Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health technology assessment in India: the potential for improved healthcare decision-making.
    Kumar M; Ebrahim S; Taylor FC; Chokshi M; Gabbay J
    Natl Med J India; 2014; 27(3):159-63. PubMed ID: 25668089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation and the rational diffusion and use of health technology.
    Drummond MF
    Health Policy; 1987 Jun; 7(3):309-24. PubMed ID: 10312123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.
    Nicod E
    Eur J Health Econ; 2017 Jul; 18(6):715-730. PubMed ID: 27538758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of Nonmarginal Budgetary Impacts in Health Technology Assessment: A Conceptual Model.
    Howdon DDH; Lomas JRS; Paulden M
    Value Health; 2019 Aug; 22(8):891-897. PubMed ID: 31426930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Technology assessment in Catalonia: integrating economic appraisal.
    Granados A; Borràs JM
    Soc Sci Med; 1994 Jun; 38(12):1643-6. PubMed ID: 8047922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Researcher-driven versus policy-driven economic appraisal of health technologies: the case of France.
    Moatti JP; Chanut C; Benech JM
    Soc Sci Med; 1994 Jun; 38(12):1625-33. PubMed ID: 8047920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Necessity under construction - societal weighing rationality in the appraisal of health care technologies.
    Kleinhout-Vliek T; de Bont A; Boer B
    Health Econ Policy Law; 2021 Oct; 16(4):457-472. PubMed ID: 32955010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are supplemental appraisal/reimbursement processes needed for rare disease treatments? An international comparison of country approaches.
    Nicod E; Whittal A; Drummond M; Facey K
    Orphanet J Rare Dis; 2020 Jul; 15(1):189. PubMed ID: 32690107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysis.
    Kaltenthaler E; Carroll C; Hill-McManus D; Scope A; Holmes M; Rice S; Rose M; Tappenden P; Woolacott N
    Health Technol Assess; 2016 Apr; 20(26):1-48. PubMed ID: 27049841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving the Efficiency and Quality of the Value Assessment Process for Companion Diagnostic Tests: The Companion test Assessment Tool (CAT).
    Canestaro WJ; Pritchard DE; Garrison LP; Dubois R; Veenstra DL
    J Manag Care Spec Pharm; 2015 Aug; 21(8):700-12. PubMed ID: 26233542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When Future Change Matters: Modeling Future Price and Diffusion in Health Technology Assessments of Medical Devices.
    Grimm SE; Dixon S; Stevens JW
    Value Health; 2016; 19(6):720-726. PubMed ID: 27712696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting.
    Angelis A; Montibeller G; Hochhauser D; Kanavos P
    BMC Med Inform Decis Mak; 2017 Oct; 17(1):149. PubMed ID: 29073892
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.